| Ytd | -7.89% | |
| 1y | 133.33% |
| Open | 1.04 | Prev Close | 1.03 | Low | 1.00 | High | 1.06 | Mkt Cap | 54.49M |
| Vol | 365.48K | Avg Vol | 180.37K | EPS | -0.28 | P/E | N/A | Forward P/E | -0.63 |
| Beta | 0.30 | Short Ratio | 0.85 | Inst. Own | 29.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 0.87 | 200-d Avg | 0.99 | 1yr Est | 4.17 |
HC Wainwright & Co. analyst Brandon Folkes assumes Talphera (NASDAQ:TLPH) with a Buy rating a
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.04) per share which beat the analyst consens
WestPark Capital analyst Ed Arce initiates coverage on Talphera (NASDAQ:TLPH) with a Buy rating a
Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.06) per share which beat the analyst consens
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new tar
Companies Reporting Before The Bell • CTS (NYSE:CTS) is estimated to report quarterly earnings at $